Skip to main content

MundiPharma-Logo

Report an adverse event

Adverse events should be reported. Reporting forms and information can be found at https://aems.tga.gov.au/

Adverse events can also be reported to Mundipharma at Drugsafety@mundipharma.com.au

Report adverse event Login Register
country country AU
  • Australia Australia (AU)
  • Brazil Brazil (BR)
  • France France (FR)
  • Germany Germany (DE)
  • Italy Italy (IT)
  • Japan Japan (JP)
  • Spain Spain (ES)
  • United Kingdom United Kingdom (UK)
  • Therapy Areas
    • Central Precocious Puberty (CPP)
    • Prostate Cancer (PCA)
    • Peripheral T-cell Lymphoma (PTCL)
  • Medicines
    • ELIGARD® FOR CPP
    • ELIGARD® for PCA
    • FOLOTYN®
  • Resources
    • Webinar & Videos
    • Other Resources
  • About Us
Report adverse event
Login Register
country country AU
  • Australia Australia (AU)
  • Brazil Brazil (BR)
  • France France (FR)
  • Germany Germany (DE)
  • Italy Italy (IT)
  • Japan Japan (JP)
  • Spain Spain (ES)
  • United Kingdom United Kingdom (UK)
Mundipharma Logo
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

* Required Fields

Report Adverse Event

Adverse events should be reported. Reporting forms and information can be found at https://aems.tga.gov.au/

Adverse events can also be reported to Mundipharma at Drugsafety@mundipharma.com.au

WELCOME BACK!

Login here to access a wide range of resources offered by the Mundipharmapro website.

Log in with OneKey

Enter your email address

Enter the password that accompanies your username

Forgot Password?

* Required Fields

Don't have an account? Register Now

Napp Logo - A member of the Mundipharma network of associated companies
country country AU
  • Australia Australia (AU)
  • Brazil Brazil (BR)
  • France France (FR)
  • Germany Germany (DE)
  • Italy Italy (IT)
  • Japan Japan (JP)
  • Spain Spain (ES)
  • United Kingdom United Kingdom (UK)
Site Directory
  • Therapy Areas
    • Central Precocious Puberty (CPP)
    • Prostate Cancer (PCA)
    • Peripheral T-cell Lymphoma (PTCL)
  • Medicines
    • ELIGARD® FOR CPP
    • ELIGARD® for PCA
    • FOLOTYN®
  • Resources
    • Webinar & Videos
    • Other Resources
  • About Us
  • CONTACT US
  • LEGAL
  • COOKIE POLICY
  • PRIVACY
  • Therapy Areas
    • Central Precocious Puberty (CPP)
    • Prostate Cancer (PCA)
    • Peripheral T-cell Lymphoma (PTCL)
  • Medicines
    • ELIGARD® FOR CPP
    • ELIGARD® for PCA
    • FOLOTYN®
  • Resources
    • Webinar & Videos
    • Other Resources
  • About Us

Copyright Mundipharma Pharmaceuticals. All Rights Reserved. | JOB CODE: AU-NPR-2200027 | Prepared: April 2022

STAY CONNECTED

Opioid Charter

Opioid Charter For Mundipharma's Charter on the responsible medical use of opioid analgesics in pain management Click Here..

Opioid Safety Statement

"Attention should be given as the use of opioids has a risk of addiction, misuse and abuse. Therefore, appropriate assessment and monitoring is required at initiation, maintenance and tapering down of opioid therapy."